Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects - Test2 - elhamkhani - TriplyDB

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

http://www.wikidata.org/entity/Q33801377

about

Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy Potential of epigenetic therapies in the management of solid tumors Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer.Aberrant methylation patterns in cancer: a clinical view.Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.Knockdown of linc-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer.Knockdown of linc-UFC1 suppresses proliferation and induces apoptosis of colorectal cancer High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer.Nutrients and the Pancreas: An Epigenetic Perspective.Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers.MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells.Current progress in immunotherapy for pancreatic cancer.Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance

P2860

Q26774080-3D7B672C-250B-42AD-B176-B476510702C0 Q26783134-44596EA3-8CF4-4E05-B3FA-FACD73661D05 Q26785691-E29881CE-D0DF-4B7A-8B01-024CA7ABB6F7 Q26799714-8ED96E3E-A5DD-4E06-8C22-C8433073F47C Q28074465-AABDFBD6-48AF-49BD-87E0-E24853507C07 Q28076548-09E803D3-DD6F-46A3-8EFD-C65AC67125B2 Q35176013-59159BB8-67ED-4706-B8C7-83FA66073577 Q35750355-C5FFBF6F-3D63-4216-900B-56E9D2C1A7CC Q36135041-8A47C5FF-3BAA-4991-800C-D4A4116458E0 Q36729578-3D9D49E1-CBAC-4203-8F24-A493FC3A0301 Q37030309-7DC2ECE0-B17B-4388-ADAD-8A148B08A4AE Q37519435-FAF3F6E7-2711-4ADE-8D79-DC53613F9C24 Q37729841-591F5BAA-7B12-4493-8DD5-448348FC8645 Q38696102-8890A2E0-0DBD-418B-8784-0B33BB7B5DB0 Q38707876-78665709-F465-4118-918B-C796036F17F0 Q38777365-38F254A3-7649-46E9-BA67-56E2D944A8EA Q38962073-B4C2EED0-D518-48CC-8B88-2679B1CFEC0B Q39108676-4E00694C-BDD4-4A0D-ACCD-5587349975FE Q39204274-DEF319B2-95FE-440C-A51C-BA9B5800E44D Q39712532-AAEBA708-EE6B-4315-A372-09E22562AE79 Q42086309-AC484852-AE9D-4A3B-B44E-804F527AA6B7 Q46712164-24B0A2A3-2D6F-4273-B30B-56BC22DD5DAE Q49853764-608C0720-8887-4D21-A353-8A031E6F512C Q51760860-9FAB9C64-E8CE-4B53-A3D3-5F21AD09C081 Q52715499-67FAA476-51D6-4324-842C-15FF03E6E052 Q52890071-3EA77BAE-1988-4839-ABA2-41719B186CD5 Q58726181-98751A0D-E77C-4EC1-AEA6-FB6DF05E9F65

P2860

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

http://www.wikidata.org/entity/Q33801377

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@ast

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@en

type

label

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@ast

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@en

prefLabel

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@ast

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@en

P1433

Q33801377-AF94309D-7C39-414E-A349-3F376762697E

P1476

Q33801377-5838B0A2-0313-4B73-BBFE-5119FEAA913D

P2093

Q33801377-82BDA8F9-F1E8-492E-9251-8943D02C26B5

Q33801377-A8C6CBA9-5573-422A-B911-3F098B19B519

P2860

Q33801377-0028480B-9D7A-4E46-8D82-B95B61A8F7C9

Q33801377-01AE74DB-404A-4961-BAF6-51F946745179

Q33801377-02E870B4-B46A-42A5-9432-EF000DA24118

Q33801377-03728183-105A-4140-96CB-21FBFC25E736

Q33801377-05EE9BF8-AD25-4364-8458-31F75B127C28

Q33801377-060DB66B-7E0C-4F53-843B-76A642D6ECA1

Q33801377-0BEC9EED-2AFA-4514-9FC3-C93CF717E917

Q33801377-0D6A4103-9122-407A-B13A-582DC03D7490

Q33801377-115813C2-6582-4D6C-9ABE-3CEC45F5CBC1

Q33801377-119BEDFA-0712-4360-8584-64157F9636F6

P304

Q33801377-11B8E572-C7F1-4C48-A683-7F536A2B7EC1

P31

Q33801377-0B16438A-8D36-4534-A1E5-709889CEC6A2

P356

Q33801377-97A981A9-703A-45E5-A594-D2F04AF07BB7

P407

Q33801377-EBC42384-978A-45B8-95D0-71989947B4DB

P433

Q33801377-55EF4525-064E-48C3-A699-77B96DE00009

P478

Q33801377-3D68563A-B4EB-45EE-B52A-888497C23881

P50

Q33801377-05AFCA23-C97C-464D-91DE-67FE895B172C

Q33801377-38D5BA25-5281-499A-A98F-42C242218B6B

P577

Q33801377-87C3CDA3-1E02-47E4-94B0-AC7D3FC741F0

P5875

Q33801377-D2582F90-A799-4AA4-B295-7A8B2C02D98A

P698

Q33801377-0475534A-D7EC-40E5-8EA4-4CC318B7D9C6

P921

Q33801377-39BCB301-FA4D-4E5C-9CCF-F4CD33B46B01

P932

Q33801377-C64D5F91-43B1-4EB8-B1EE-7E8E0449F19F

P356

WJG.V20.I24.7830

P1433

World Journal of Gastroenterology

P1476

Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

@en

P2093

Daniel Neureiter

http://www.w3.org/2001/XMLSchema#string

Matthias Ocker

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

The Hallmarks of Cancer

Global cancer statistics

Hallmarks of Cancer: The Next Generation

Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer

miRBase: microRNA sequences, targets and gene nomenclature

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

MicroRNAs: target recognition and regulatory functions

P304

7830-7848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I24.7830

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Tobias Kiesslich

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263514853

http://www.w3.org/2001/XMLSchema#string

P698

24976721

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

4069312

http://www.w3.org/2001/XMLSchema#string